

COMPLETE LIST OF CLAIMS

Claim 1 (Canceled)

Claim 2 (Previously presented): A water soluble tin mesoporphyrin compound comprising a tin mesoporphyrin complexed with at least one amino acid, wherein the compound is water soluble.

Claim 3 (Previously presented): The water soluble tin mesoporphyrin compound of claim 2, wherein the compound is in liquid or solid form.

Claim 4 (Previously presented): The water soluble tin mesoporphyrin compound of claim 2, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine and combinations thereof.

Claim 5 (Previously presented): A pharmaceutical formulation comprising a water soluble tin mesoporphyrin compound comprising a tin mesoporphyrin complexed with at least one amino acid and at least one pharmaceutically acceptable carrier, wherein the compound is water soluble.

Claims 6-7 (Canceled)

Claim 8 (Previously presented): The pharmaceutical formulation of claim 5, wherein the water soluble compound is in liquid or solid form.

Claim 9 (Previously presented): The pharmaceutical formulation of claim 5, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine and combinations thereof.

Claim 10 (Previously presented): The pharmaceutical formulation of claim 5, wherein the formulation contains between about 0.1 and about 50 mg of tin mesoporphyrin dichloride.

Claims 11 – 33 (Canceled)

Claim 34 (Previously presented): A method of treating a human being with a heme metabolism disorder comprising administering to said human being a pharmaceutically effective

amount of a water soluble tin mesoporphyrin compound comprising a tin mesoporphyrin complexed with at least one amino acid.

Claim 35 (Previously presented): The method of claim 34, wherein the amino acid is selected from the group consisting of arginine, glycine, alanine, leucine, serine, lysine, histidine, phenylalanine, tyrosine and combinations thereof.

Claim 36 (Previously presented): The method of claim 35, wherein the disorder is hyperbilirubinemia.

Claim 37 (Previously presented): The method of claim 35, wherein the disorder is psoriasis.

Claim 38 (New): The water-soluble tin mesoporphyrin compound of Claim 2, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannsoporphin).

Claim 39 (New): The water-soluble tin mesoporphyrin compound of Claim 3, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannsoporphin).

Claim 40 (**New**): The water-soluble tin mesoporphyrin compound of Claim 4, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 41 (**New**): The pharmaceutical formulation of Claim 5, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 42 (**New**): The pharmaceutical formulation of Claim 8, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 43 (**New**): The pharmaceutical formulation of Claim 9, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 44 (**New**): The pharmaceutical formulation of Claim 10, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 45 (**New**): The method of Claim 34, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannsoporfin).

Claim 46 (**New**): The method of Claim 35, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannosoporphin).

Claim 47 (**New**): The method of Claim 36, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannosoporphin).

Claim 48 (**New**): The method of Claim 37, wherein said tin mesoporphyrin is tin (IV) mesoporphyrin IX dichloride (or stannosoporphin).